John R. Stuelpnagel, Director at 10x Genomics, Inc. (TXG), sold 8,500 shares at $154.45 ($1.3M) on 2021-09-16, disclosed to the SEC on 2021-09-20.
Open-market sale of $1.3M TXG by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $154.45 | 700 | $108K | 8.1% |
| 2 | $154.45 | 700 | $108K | 8.1% |
| 3 | $155.69 | 1,500 | $234K | 17.6% |
| 4 | $156.72 | 1,631 | $256K | 19.2% |
| 5 | $156.72 | 1,631 | $256K | 19.2% |
| 6 | $157.75 | 1,169 |
| $184K |
| 13.9% |
| 7 | $157.75 | 1,169 | $184K | 13.9% |
| Total | $156.45 avg | 8,500 | $1.3M | 100% |
| Filing → |
| TXG | SELL | 2023-06-07 | $549K | — | Filing → |
| TXG | SELL | 2022-01-04 | $1.5M | — | Filing → |
| TXG | SELL | 2021-12-03 | $756K | — | Filing → |